Stock Analysis on Net

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Pfizer Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Short-term borrowings, including current portion of long-term debt 6,946 9,699 11,944 8,232 10,350 2,548 3,985 4,188 2,945 4,040 5,990 645 2,241 3,629 3,888 4,352 2,703 13,363 13,084 16,007
Trade accounts payable 5,633 5,314 5,106 5,591 6,710 5,338 6,081 6,123 6,809 6,267 6,208 5,506 5,578 4,698 4,327 4,064 4,309 4,141 3,872 3,972
Dividends payable 2,437 2,380 2,372 2,315 2,303 2,245 2,245 2,249 2,191 2,184 2,162 2,112 2,111
Income taxes payable 2,910 2,877 2,884 3,192 2,349 1,898 2,928 1,969 1,587 3,071 3,350 3,177 1,266 4,496 1,742 1,401 1,049 1,430 1,445 1,150
Accrued compensation and related items 3,838 3,383 2,566 2,192 2,776 2,372 1,972 2,277 3,407 2,852 1,997 2,249 3,332 2,571 2,015 1,985 3,058 2,425 2,042 2,246
Deferred revenues 1,511 2,020 2,528 2,502 2,700 2,204 1,286 1,750 2,520 6,191 3,804 3,108 3,067 3,529 4,291 2,052 1,113
Other current liabilities 19,720 19,918 16,411 18,788 20,537 16,776 16,080 20,255 22,567 19,648 23,816 24,583 24,938 20,689 17,217 12,798 11,526 10,683 10,169 10,515
Current liabilities 42,995 43,211 43,819 40,497 47,794 31,136 34,647 36,562 42,138 44,314 47,410 39,268 42,671 41,803 35,664 26,652 25,920 34,154 32,723 33,890
Long-term debt, excluding current portion 57,405 58,002 57,506 61,307 61,538 61,048 61,356 31,704 32,884 32,629 34,294 35,656 36,195 36,250 35,354 35,347 37,133 49,785 50,529 36,281
Pension and postretirement benefit obligations 2,115 2,073 2,040 2,076 2,167 2,166 2,184 2,179 2,250 2,960 3,257 3,494 3,724 4,303 4,939 5,161 5,411 6,437 6,430 6,535
Noncurrent deferred tax liabilities 2,122 2,158 2,227 931 640 1,125 1,232 1,067 1,023 616 558 655 349 328 4,161 4,355 4,063 4,542 5,409 5,268
Other taxes payable 6,112 5,905 6,532 8,603 8,534 8,099 8,052 9,860 9,812 9,701 10,990 11,574 11,331 11,336 11,259 11,759 11,560 11,720 11,468 12,212
Other noncurrent liabilities 14,150 15,569 16,094 15,123 16,540 14,243 13,404 13,009 13,181 12,239 11,312 10,508 9,743 9,201 8,228 6,679 6,669 6,849 6,811 6,812
Noncurrent liabilities 81,904 83,707 84,399 88,040 89,419 86,681 86,228 57,819 59,150 58,145 60,411 61,887 61,342 61,418 63,941 63,301 64,836 79,333 80,647 67,108
Total liabilities 124,899 126,918 128,218 128,537 137,213 117,817 120,875 94,381 101,288 102,459 107,821 101,155 104,013 103,221 99,605 89,953 90,756 113,487 113,370 100,998
Preferred stock 17
Common stock 480 480 480 480 478 478 478 478 476 476 476 476 473 473 472 472 470 470 471 470
Additional paid-in capital 93,603 93,477 93,197 92,997 92,631 92,496 92,329 92,153 91,802 91,359 91,183 90,844 90,591 89,973 89,336 89,002 88,674 88,161 87,886 87,680
Treasury stock (114,763) (114,760) (114,757) (114,755) (114,487) (114,485) (114,482) (114,473) (113,969) (113,945) (113,939) (113,932) (111,360) (111,358) (111,354) (111,348) (110,988) (110,980) (110,978) (111,010)
Retained earnings 116,725 121,060 116,596 121,318 118,353 126,411 128,796 131,101 125,656 122,966 116,607 111,193 103,394 102,252 96,346 95,158 96,770 100,284 100,203 101,000
Accumulated other comprehensive loss (7,842) (7,971) (7,816) (7,758) (7,961) (7,966) (8,102) (8,289) (8,304) (8,225) (7,119) (6,157) (5,897) (5,649) (4,758) (4,664) (11,688) (12,676) (13,246) (13,131)
Total Pfizer Inc. shareholders’ equity 88,203 92,286 87,700 92,282 89,014 96,934 99,019 100,970 95,661 92,631 87,208 82,424 77,201 75,691 70,042 68,620 63,238 65,259 64,336 65,026
Equity attributable to noncontrolling interests 294 272 275 276 274 270 274 266 255 260 261 261 261 276 273 245 235 236 228 312
Total equity 88,497 92,558 87,975 92,558 89,288 97,204 99,293 101,236 95,916 92,891 87,469 82,685 77,462 75,967 70,315 68,865 63,473 65,495 64,564 65,338
Total liabilities and equity 213,396 219,476 216,193 221,095 226,501 215,021 220,168 195,617 197,204 195,350 195,290 183,840 181,475 179,188 169,920 158,818 154,229 178,982 177,934 166,336

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Pfizer Inc. current liabilities decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Pfizer Inc. noncurrent liabilities decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Pfizer Inc. total liabilities decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Total Pfizer Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Pfizer Inc. total Pfizer Inc. shareholders’ equity increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.